Earnings ·
Aclaris Therapeutics reports Q3 net loss of $18.5M and raises $50M via equity offering
ACRSAclaris Therapeutics, Inc.
Aclaris Therapeutics reported a third-quarter 2026 net loss of $18.5 million, compared to $14.6 million in the prior year period, with total revenue declining to $1.5 million from $3.3 million due to lower licensing milestone receipts. The company also raised $50.0 million in gross proceeds through an October equity offering of 7.8 million shares and pre-funded warrants for 6.5 million shares. As of September 30, 2026, the firm held $204.6 million in cash and marketable securities, providing a runway to fund operations through the first half of 2029. Clinically, Aclaris announced positive Phase 1b results for ATI-052 in atopic dermatitis and asthma, plans to prioritize eosinophilic esophagitis development for ATI-052, and expects to initiate a Phase 2b trial for modzatinib in lichen planus in the fourth quarter of 2026. Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases.